| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NRX Pharmaceuticals, Inc.$3.95
+0.07 (+1.81%)
Market Cap
116.66 M
EPS
-1.28
P/E Ratio
-
Value Trade
17.78 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.07 M
R&D Expenses
1.31 M
Operating CF
-4.29 M
Total Assets
11.90 M
Total Liabilities
25.72 M
Equity
-13.82 M
D/E Ratio
12,345
-0.92 %
Week
5.92 %
1 Month
76.92 %
3 Month
61 %
6 Month
-98.94 %
5 Year
-96.65 %
All Time
Cash Data
Cash Position
6.71 M
Monthly Burn
1.43 M
Runway
3.1 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
620.50 K
52 Week Range
1.62 - 3.84
% held by Insiders
11.62 %
% held by Institutions
15.03 %
Enterprise Value
110.88 M
Total Shares
36.22 M
Short %
15.4 %
Float Shares
31.01 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NRX Pharmaceuticals, Inc.
586Total events
6Upcoming
193Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 6
Event history 580
Q3 2026
Q3 2026
●PDUFA DateKETAFREE™Regulatory Filing
Anticipated FDA decision on ANDA for Preservative-Free Ketamine in Q3 2026
preservative-free ketaminesource ↗
Jul 2026
◆PDUFA DateNRX-100ApprovedRegulatory Filing
PDUFA decision date for NRX-100 ANDA
Suicidal ideation in Depressionsource ↗
Q3 2026
◆FDA ApprovalKETAFREE™FDA Decision
Anticipated FDA approval of preservative-free ketamine ANDA
Jul 2026
▲Product LaunchNRX-100ApprovedPost-Market
Anticipated July 2026 launch of preservative-free ketamine
Jun 25, 2026
▲First Patient DosedTrial
First patients treated with Zeta TMS Navigation System at HOPE Therapeutics clinics
Major Depressive Disorder and other CNS conditionssource ↗
Jun 25, 2026
▲IND ClearanceNRX-101IND
FDA clearance of IND for SPARC-TMS trial combining NRX-101 with robotic neuronavigated TMS
suicidal depressionsource ↗
Jun 24, 2026
▼IP Litigation RulingIP / Competition
Kadima Neuropsychiatry Institute files suit against NRx Pharmaceuticals for breach of contract and misrepresentation
Jun 23, 2026
▲First Patient DosedTrial
First patient treated with Zeta TMS Navigation System at HOPE Therapeutics clinic
treatment-resistant depressionsource ↗
Jun 22, 2026
▲IND ClearanceNRX-101IND
FDA approved Expanded Access Protocol for NRX-101 augmentation of TMS
Treatment-Resistant Depressionsource ↗
Jun 22, 2026
▲Trial InitiationNRX-101Trial
Initiation of pivotal SPARC-TMS trial for NRX-101 augmentation of TMS
Treatment-Resistant Depression and Suicidalitysource ↗
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IV ketamine Fast Track | treatment resistant depression | — | 2026-06-05 | remission rate iv: 34%; response rate iv: 63%; remission rate nasal esketamine: 26%; response rate nasal esketamine: 58%; odds ratio remission: 1.51; p value remission: <.001; odds ratio response: 1.22; p value response: <.003 Read More | NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. Read More | |
IV ketamine Fast Track | treatment resistant depression | — | 2026-06-05 | remission rate iv: 34%; response rate iv: 63%; remission rate nasal esketamine: 26%; response rate nasal esketamine: 58%; odds ratio remission: 1.51; p value remission: <.001; odds ratio response: 1.22; p value response: <.003 Read More | NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. Read More | |
IV ketamine Fast Track | treatment resistant depression | — | 2026-06-05 | remission rate iv: 34%; response rate iv: 63%; remission rate nasal esketamine: 26%; response rate nasal esketamine: 58%; odds ratio remission: 1.51; p value remission: <.001; odds ratio response: 1.22; p value response: <.003 Read More | NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NRXP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NRXP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NRXPNRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
NRx Pharmaceuticals has responded to Kadima Neuropsychiatry Institute's recent allegations regarding a failed acquisition by HOPE Therapeutics. NRx has initiated arbitration due to Kadima's failure to meet key conditions. The company emphasizes its focus on drug development and innovative treatments, particularly in personalized medicine and TMS technology, despite the ongoing dispute.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has initiated treatments using the FDA-cleared Zeta TMS Navigation System at its clinics in Florida. This marks a significant transition to active patient care, utilizing AI for precise targeting in TMS therapies for Major Depressive Disorder and other CNS conditions. The deployment supports HOPE's interventional psychiatry platform and aligns with planned clinical trials for NRX-101.
Read more →NRXPKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
Kadima Neuropsychiatry Institute has initiated legal proceedings against NRx Pharmaceuticals, claiming breach of contract and misrepresentation related to an acquisition. This lawsuit could have significant repercussions for NRx, potentially affecting its reputation and financial standing. The outcome of this case remains uncertain as it unfolds in the legal system.
Read more →NRXPZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
ZETA SURGICAL and HOPE Therapeutics announced the successful treatment of the first patient using the Zeta TMS Navigation System, which is FDA-cleared. This system utilizes advanced AI and computer vision for precise targeting in TMS therapy, primarily for treatment-resistant depression. The technology aims to enhance patient outcomes and expand access to personalized care.
Read more →NRXPNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
NRx Pharmaceuticals has received FDA approval for an Expanded Access Protocol for NRX-101, a combination of D-cycloserine and lurasidone, aimed at augmenting Transcranial Magnetic Stimulation (TMS) for patients with Treatment-Resistant Depression. This protocol allows patients who cannot participate in clinical trials to access the treatment. The company is also conducting a pivotal trial to assess the efficacy of NRX-101 in achieving remission from depression and suicidality.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals announced a presentation at the American Society of Clinical Psychopharmacology, highlighting a study comparing IV ketamine and nasal esketamine for treating depression. The study found that IV ketamine resulted in higher remission and response rates among patients. However, it noted limitations due to non-randomized treatment assignments and potential confounding variables.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
NRx Pharmaceuticals, Inc. has announced the successful closing of a public offering, raising approximately $22.3 million in gross proceeds. The funds are aimed at supporting working capital and general corporate purposes as the company continues its efforts in developing treatments for central nervous system disorders. The offering was completed following an effective shelf registration statement with the SEC. NRx's CEO emphasized the company's commitment to addressing critical mental health issues.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
NRx Pharmaceuticals, Inc. has announced the pricing of a public offering of 5,714,286 shares of its common stock at $3.50 per share, aiming to raise approximately $20 million. The offering includes an option for underwriters to purchase additional shares, potentially increasing proceeds to $23 million. The funds will support working capital and corporate growth, with the offering expected to close on June 4, 2026.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
NRx Pharmaceuticals, Inc. has announced a proposed public offering of its common stock to raise capital for working and corporate purposes. The offering will be underwritten, with a potential additional purchase option for the underwriter. The company has received designations for its therapeutic products aimed at treating central nervous system disorders, which may enhance its market position.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
NRx Pharmaceuticals, in collaboration with Emobot Health, presented clinical validation for EMOCARE, a smartphone-based tool for monitoring depression, at the ASCP 2026 meeting. The pooled analysis of three studies showed a 90% concordance with clinician-rated scales, indicating EMOCARE's effectiveness in tracking patient symptoms continuously. This innovation aims to enhance treatment monitoring in psychiatric care.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has become the first commercial site to implement Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach clinic. This system will provide high-precision Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions. The deployment aligns with NRx's clinical trial plans for NRX-101, enhancing treatment options for patients.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
NRx Pharmaceuticals reported its Q1 2026 financial results, highlighting significant progress in its drug development pipeline. The company anticipates an FDA decision on its ANDA for Preservative-Free Ketamine in Q3 2026 and has initiated commercial manufacturing. NRx also generated its first revenue from psychiatry clinics and appointed a new Chief Medical Innovation Officer. Despite a net loss, the company is optimistic about its growth and upcoming regulatory milestones.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
NRx Pharmaceuticals, Inc. will release its first quarter 2026 financial results on May 18, 2026, before market opening. A conference call will follow at 8:00 AM ET, allowing stakeholders to gain insights into the company's performance. NRx is known for its development of therapeutics targeting central nervous system disorders.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
NRx Pharmaceuticals has received FDA clearance to start a clinical trial for NRX-101, a combination of D-cycloserine and lurasidone, in patients with depression and suicidality. The trial will assess the drug's effectiveness alongside robotic-assisted Transcranial Magnetic Stimulation (TMS). Conducted at multiple sites, including military facilities, the study aims to enroll 400 patients, targeting non-dilutive funding for support.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
NRx Pharmaceuticals has announced the initiation of commercial manufacturing for its preservative-free ketamine product, anticipating approval under the Generic Drug User Fee Act in Summer 2026. The company has completed necessary audits and is prepared for pre-approval inspection. The manufacturing process is designed to support significant market penetration and can be scaled as demand increases.
Read more →NRXPNRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
NRx Pharmaceuticals has received a positive Discipline Review Letter from the FDA Office of Generic Drugs regarding its preservative-free ketamine program. The letter requests only minor administrative changes, and FDA leadership expressed support for the approval of the Abbreviated New Drug Application within the current review cycle. This initiative aligns with the President's Executive Order aimed at expediting treatments for severe mental health conditions.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
NRx Pharmaceuticals has welcomed a new Executive Order aimed at accelerating the approval of psychedelic medications for treating serious mental illnesses such as depression and PTSD. The order, signed by President Trump, emphasizes innovative research and collaboration among federal agencies to expedite drug approvals. NRx has received Fast Track designation for its drug NRX-100 and is preparing for a New Drug Application. This initiative is seen as a significant step towards addressing the mental health crisis in America.
Read more →NRXPNRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
NRx Pharmaceuticals has launched NRx Defense Systems, Inc. to develop neuroplastic therapies combining D-cycloserine and robotic-enabled Transcranial Magnetic Stimulation (TMS) for military and first responders. Led by Dr. Dennis McBride, the initiative aims to address mental health issues like PTSD and depression. The prototype will be unveiled at the Clinical TMS Society meeting in June 2026.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer
NRx Pharmaceuticals has appointed Glenn Tyson as its first Chief Commercial Officer. Tyson, who has over 25 years of experience in the pharmaceutical industry, will lead the company's commercial efforts as it prepares for the anticipated approval of its preservative-free ketamine product. NRx is also working on expanding the use of intravenous ketamine for treating severe depression.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
NRx Pharmaceuticals has received preliminary alignment on labeling for its preservative-free ketamine product from the FDA. This is a crucial step towards final approval, anticipated under the Generic Drug User Fee Act in Summer 2026. The product aims to address supply shortages of ketamine in the US, which is currently facing backorders from multiple suppliers.
Read more →NRXPHope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
Hope Therapeutics has partnered with Emobot Health to integrate its AI-powered 'Depression Thermometer' into its interventional psychiatry clinics. This technology aims to monitor patients' mental health passively, addressing the issue of undetected relapses in treatment-resistant depression. Clinical studies validate its effectiveness, and the integration is expected to significantly improve patient outcomes.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
NRx Pharmaceuticals reported significant progress in 2025, including reduced operating expenses and a debt-free status. The company anticipates FDA approval for its preservative-free ketamine and is expanding its neuroplastic therapy clinics. With a focus on innovative treatments for severe depression and PTSD, NRx aims to enhance patient care and revenue growth moving forward.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
NRx Pharmaceuticals, Inc. announced a conference call for March 24, 2026, to discuss its financial results for the year 2025 and provide an update on its drug development progress. The company focuses on therapeutics for central nervous system disorders, particularly aimed at treating suicidal depression and PTSD. NRx is actively developing treatments, including NRX-100 and NRX-101, both of which have received significant regulatory designations to expedite their development. The call will be accessible via webcast and telephone for stakeholders and interested parties.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
NRx Pharmaceuticals announced that the FDA's Office of Generic Drugs has not found any bioequivalence deficiencies in its preservative-free ketamine application. This determination is preliminary, pending final review. The company anticipates a decision on its ANDA application by Summer 2026, aiming to provide a safer alternative in the ketamine market. The product is significant as it eliminates a toxic preservative previously thought necessary for stability.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
NRx Pharmaceuticals has received confirmatory minutes from the FDA following a Type C meeting, outlining a path to New Drug Approval for NRX-100, a formulation of preservative-free ketamine. The FDA has agreed to review existing clinical trial data alongside Real World Evidence to establish the drug's efficacy for treating severe depression, including patients with suicidality. The company plans to submit its New Drug Application by June 2026, marking a significant step towards addressing a critical mental health need in the U.S.
Read more →NRXPHOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has opened a new clinic in Palm Beach, FL, focusing on treating Depression and PTSD using advanced neuroplastic therapies. The clinic employs a combination of ketamine, transcranial magnetic stimulation (TMS), and hyperbaric oxygen therapy. Published studies report high clinical response rates, with 87% for treatment-resistant depression and 90% for patients returning to full function.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
NRx Pharmaceuticals has appointed Prof. Joshua Brown as Chief Medical Innovation Officer. Prof. Brown is a distinguished psychiatrist and neuroscientist known for his work in Transcranial Magnetic Stimulation (TMS) and neuroplastic medications. He aims to accelerate the development of evidence-based treatments for PTSD and depression, particularly for military personnel and first responders.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
NRx Pharmaceuticals has announced a path to file a New Drug Application for NRX-100 following a Type C meeting with the FDA. The company aims to utilize existing clinical trial data and Real World Evidence from over 65,000 patients to support its application. The FDA indicated that no further nonclinical data or bridging studies are required, facilitating the approval process. NRx plans to broaden the indication for NRX-100 to include treatment-resistant depression in patients with suicidality.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
NRx Pharmaceuticals has scheduled its 2025 Annual Meeting for March 23, 2026, in a virtual format. The record date for stockholders to vote is set for February 12, 2026. The company will provide further details in its proxy statement. Stockholders must submit proposals by January 26, 2026, to be considered at the meeting.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
NRx Pharmaceuticals has announced the submission of real-world evidence from over 70,000 patients to the FDA in support of NRX-100, a preservative-free ketamine treatment for suicidal ideation. This data, provided by Osmind, aims to secure Accelerated Approval under Fast Track Designation. The initiative highlights the urgent need for effective treatments for suicidal depression, as current options are limited.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
NRx Pharmaceuticals and neurocare Group AG have announced a partnership to establish a nationwide network of clinics offering integrated neuroplastic therapy for mental health disorders such as Depression and PTSD. Initial pilot programs indicate promising remission rates, and the collaboration aims to address the fragmented nature of current treatment options. The initiative is set to enhance accessibility to innovative therapies across the United States by the end of 2026.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
NRx Pharmaceuticals has successfully eliminated its remaining $5.4 million balance sheet debt through the conversion of equity into common stock, with no additional warrants or adjustments. The company expects to end 2025 free of all debt, which it believes will facilitate accelerated growth in 2026, particularly with upcoming drug approvals and clinic expansions. NRx’s leadership expressed gratitude to Anson Funds for their support, emphasizing their commitment to advancing treatments for suicidal depression and PTSD.
Read more →NRXPNRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
NRx Pharmaceuticals announced that the FDA has received its ANDA for KETAFREE™, a preservative-free IV ketamine formulation. The FDA's acknowledgment indicates the application is substantially complete, with a review goal date set for July 29, 2026. This development aligns with efforts to enhance drug safety and supply in the U.S.
Read more →NRXPNRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
NRx Pharmaceuticals has amended its Investigational New Drug filing for NRX-101, now allowing its use in conjunction with Transcranial Magnetic Stimulation (TMS) for treating depression, including suicidal depression. New evidence suggests NRX-101, a combination of D-cycloserine and lurasidone, significantly enhances the therapeutic effects of TMS, with reported clinical response rates of 87%. The company is also pursuing partnerships for clinical trials that could lead to drug registration and the augmentation of TMS device labeling.
Read more →NRXPNRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
NRx Pharmaceuticals will hold a corporate update conference call on December 2, 2025, at 9:00 AM ET. The call will cover recent clinical, regulatory, and operational updates. NRx is focused on developing neuroplastic therapies for mental health disorders and has received Fast Track and Breakthrough Therapy designations for its drug candidates.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NRx Pharmaceuticals, Inc. reported its financial results for Q3 2025 and provided various corporate updates. The company has refiled its Abbreviated New Drug Application for KETAFREE™ and received supportive correspondence from the FDA, anticipating a GDUFA date in Q2 2026. NRx also announced the expansion of HOPE Therapeutics, aiming to address mental health disorders with new facilities in Florida. Financially, the company faced an increased operational loss, attributed to additional R&D expenses, while its drug development initiatives continue to progress positively.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
NRx Pharmaceuticals, Inc. has announced it will release its third quarter 2025 financial results on November 17, 2025. The release will be accompanied by a conference call for a corporate and financial update. The company's developments include investigational therapeutics for central nervous system disorders, particularly targeting suicidal ideation in patients with depression. Noteworthy is the awarding of Fast Track and Breakthrough Therapy designations to its key products, NRX-100 and NRX-101.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
NRx Pharmaceuticals, Inc. will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. CEO Jonathan Javitt will discuss the planned launch of a low-dose D-Cycloserine product aimed at enhancing treatment effectiveness for depression. The company is also focusing on expanding its clinical operations in Florida and engaging with the US Department of Veterans Affairs to support veterans suffering from suicidal depression and PTSD.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
NRx Pharmaceuticals has re-filed its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine. This filing follows the FDA's approval of its Suitability Petition for the new formulation, which seeks to address safety concerns by eliminating toxic preservatives. The current ketamine market is estimated at $750 million, expected to grow significantly, as demand continues amid a national shortage. The company aims to capture this market while also resourcing the production of ketamine domestically in line with U.S. regulatory priorities.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
NRx Pharmaceuticals, Inc. has received notification from the FDA regarding the approval of its Suitability Petition for a preservative-free ketamine product, KETAFREE. This approval allows the company to re-file its Abbreviated New Drug Application, reflecting a shift from multi-dose to single-patient dosing. The firm aims to address public health trends focused on removing toxic substances from pharmaceuticals while also tapping into a significant market opportunity for ketamine, valued at approximately $750 million. Additionally, NRx is pursuing other innovative treatments for mental health conditions such as suicidal depression and PTSD.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
NRx Pharmaceuticals will be represented by CEO Jonathan Javitt at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025. The event will include a fireside chat and one-on-one meetings with investors. NRx specializes in developing therapies for central nervous system disorders, with promising designations for its products NRX-100 and NRX-101 aimed at treating suicidal depression and bipolar depression.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
NRx Pharmaceuticals, Inc. announced plans for the launch of HOPE Therapeutics clinics in September 2025, focusing on treatments for mental health disorders such as suicidal depression and PTSD. The initiative will combine neuroplastic drugs with already-approved treatments in a unique patient-friendly setup. Recently, the company raised $8.8 million from biotech investors to support the rollout. Additionally, Matthew Rockefeller has joined the HOPE Therapeutics Advisory Board to enhance the project's vision and execution.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)
NRx Pharmaceuticals, Inc. has announced an expanded access policy for its drug NRX-100, following the FDA's Fast Track designation for treating suicidal ideation associated with depression, including bipolar depression. This initiative allows physicians to request NRX-100 for their patients who face serious or life-threatening depression and have not found relief through existing therapies. The company emphasizes the urgent need for effective treatment options in this critical patient population.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported its second quarter financial results for 2025, highlighting notable progress in its drug development initiatives. The company received an expanded Fast Track Designation for NRX-100 from the FDA, broadening its potential market significantly. They also submitted applications for various regulatory programs, including a National Priority Voucher for NRX-100, while managing concerns about the safety of a commonly used preservative in current ketamine products. The recent investment from a consortium of biotechnology investors further supports the company’s goals to advance its drug formulations and overall business strategy.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025
NRx Pharmaceuticals has rescheduled its second quarter 2025 financial results release to August 19, 2025, due to the need for additional time to compile necessary information. A conference call will follow on August 20, 2025. The company is focused on developing treatments for central nervous system disorders and has received designations for its products aimed at suicidal depression.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
NRx Pharmaceuticals has received FDA Fast Track designation for NRX-100, aimed at treating suicidal ideation in patients with depression, including bipolar depression. This designation significantly expands the potential patient population compared to previous approvals. The company plans to submit further data to expedite the review process, highlighting promising clinical trial results.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
NRx Pharmaceuticals, Inc. will release its second quarter 2025 financial results on August 14, 2025, following a conference call at 4:30 PM ET. The call will provide updates on regulatory events and future operational plans. The company is focused on developing therapies for suicidal depression and related disorders, with significant regulatory designations received for its products NRX-100 and NRX-101. Participants can access the conference via telephone or a live webcast on the company's website.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, has received final clearance from the Florida Agency for Health Care Administration to close its acquisition of Dura Medical LLC. This acquisition is significant as Dura Medical provides advanced mental health treatments and aims to expand its services to treat over 10,000 individuals by 2026. The acquisition is seen as a strategic move to enhance HOPE's network in Florida.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products
NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove Benzethonium Chloride from ketamine products due to its known toxicity. The company is also pursuing a preservative-free ketamine formulation and aims to treat suicidal depression with its investigational therapies. This initiative aligns with current health priorities to eliminate harmful additives from medications.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025
NRx Pharmaceuticals, Inc. will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 30, 2025. CEO Prof. Jonathan Javitt will discuss neuroplasticity in treating CNS disorders alongside experts from Yale and BTIG. The company is advancing its investigational therapies, including NRX-101 for bipolar depression and NRX-100 for suicidal depression.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed a Letter of Intent to acquire a 49% interest in Cohen and Associates, a leading Interventional Psychiatry clinic. This acquisition aims to enhance HOPE's network in Florida, providing advanced treatments for CNS disorders. Dr. Rebecca Cohen, a recognized expert in TMS, will lead the clinic's operations.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)
NRx Pharmaceuticals has filed for the FDA's new Commissioner's National Priority Voucher program for its NRX-100, a preservative-free ketamine formulation. This program aims to expedite drug approvals for treatments addressing national health priorities, such as suicidal depression and PTSD. NRx believes it meets the criteria for the program and is preparing for a New Drug Application. The company is also addressing the safety concerns of traditional ketamine formulations.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
NRx Pharmaceuticals and HOPE Therapeutics have formed a strategic investor relations partnership with astr partners. This collaboration aims to enhance visibility and strengthen investor relationships at a pivotal moment for NRx, which is nearing multiple NDA filings and expanding its clinic network. The partnership is expected to amplify the companies' value story in the life sciences sector.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 16-17, 2025. Dr. Jonathan Javitt will deliver a corporate presentation detailing the latest advancements in their therapeutics, particularly NRX-101, which targets suicidal bipolar depression and chronic pain. The presentation will be available on demand for registered attendees.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine
NRx Pharmaceuticals has filed an Abbreviated New Drug Application for NRX-100, a preservative-free IV ketamine formulation, targeting existing approved uses like anesthesia and pain management. The company aims to capture a significant share of the growing ketamine market, currently estimated at $750 million. NRx is also seeking priority FDA review and plans to file a citizen's petition to remove harmful preservatives from ketamine formulations.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida
NRx Pharmaceuticals, Inc. will be presenting at the Wall Street Conference on May 21, 2025, highlighting their advancements toward FDA approval of their investigational treatment NRX-100. CEO Jonathan Javitt will provide an update on the company's strategies, including plans for acquiring HOPE clinics aimed at treating suicidal depression, PTSD, and related disorders. The conference hosts a prominent audience with significant investment interest, underlining the company's potential within the biopharmaceutical landscape.
Read more →NRXPHOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has announced a $7.8 million debt financing agreement with Universal Capital to support its clinic acquisition strategy. This funding is part of a larger financing plan, which will total approximately $10.3 million, to facilitate the acquisition of leading clinics that provide neuroplastic treatments for conditions such as severe depression and PTSD. The company aims to establish a nationwide network of clinics to address the growing mental health crisis in the United States.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
NRx Pharmaceuticals, Inc. reported its financial results for Q1 2025, highlighting progress towards FDA approval for two of its key drugs, NRX-100 and NRX-101. The company completed a convertible note offering, securing sufficient capital to sustain operations through 2025. Both drugs are being developed to treat serious mental health conditions, with NRX-100's NDA filing expected in Q2 2025 and a patent application filed for its preservative-free formulation. Additionally, NRx is advancing its clinic network under HOPE Therapeutics, with significant expected revenue from new acquisitions.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute in La Jolla, CA. This acquisition aims to serve as a clinical model for HOPE's network of interventional psychiatry clinics, enhancing its treatment offerings in the U.S. Kadima is noted for its role in CNS and psychedelic research and has a profitable track record. Dr. David Feifel, a leading expert in interventional psychiatry, will become HOPE's Chief Medical Innovation Officer following the acquisition.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025
NRx Pharmaceuticals, Inc. has announced that it will release its first-quarter 2025 financial results on May 15, 2025, after market closure. The company will also host a conference call to discuss the results and provide a corporate update on the same day. Notably, NRx is developing NRX-101, an investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain, which has received Breakthrough Therapy designation from the FDA.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, will host an investor event on May 8, 2025, at the Mar-A-Lago Club in Florida to discuss strategic initiatives and clinical progress. Key topics include the expansion of HOPE's interventional psychiatry network, the integration of digital health solutions, and updates on the New Drug Application for NRX-100. Investors will receive updates on recent acquisitions and potential market exclusivity for NRX-100 if its patent is granted. The company aims to enhance mental health treatment capabilities and regulatory achievements.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine
NRx Pharmaceuticals, Inc. announced the filing of a patent application for NRX-100, a preservative-free intravenous ketamine formulation aimed at treating suicidal depression. This patent, if granted, would provide market exclusivity until 2045 and enhances NRx's strategy in developing safe treatments. The formulation eliminates preservatives linked to toxicity, aligning with regulatory trends and expressing the company's commitment to patient well-being. NRx also aims to submit a New Drug Application for NRX-100 based on clinical trial results and collaboration with international health authorities.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression
NRx Pharmaceuticals, Inc. has announced that it received a filing fee waiver from the FDA for its upcoming New Drug Application (NDA) for NRX-100, a preservative-free ketamine. This exemption from a $4.3 million fee is crucial as it will allow the company to proceed with the NDA filing anticipated by Q2 2025. NRX-100 aims to provide a safer alternative for treating suicidal depression, alongside the endorsement of psychedelic therapies from health authorities.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
NRx Pharmaceuticals and HOPE Therapeutics will participate in an H.C. Wainwright fireside chat on April 22, 2025. Jonathan Javitt, CEO of NRx, will lead the discussion, which aims to engage investors and provide insights into the companies' strategies. NRx is focused on developing treatments for central nervous system disorders, including NRX-101 for suicidal bipolar depression. The event indicates the companies' commitment to transparency and investor relations.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
HOPE Therapeutics, Inc. has signed a term sheet with a global medical device manufacturer for a $2.5 million investment to develop its interventional psychiatry network. This investment aims to enhance treatment options for patients suffering from suicidal depression and PTSD. The deal is contingent upon a definitive Stock Purchase Agreement and will help support the acquisition of additional clinics. The investment reflects HOPE's growth strategy in addressing the unmet needs in mental health care.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
HOPE Therapeutics, Inc. has announced a definitive purchase agreement to acquire Dura Medical, enhancing their interventional psychiatry services on the west coast of Florida. This follows a previously announced acquisition of the Neurospa TMS network to provide a comprehensive service offering for mental health treatment, including ketamine therapy and TMS. Dura Medical is positioned as a revenue-generating entity with a mission to treat over 10,000 patients by 2026. Stephen Durand, the founder of Dura Medical, will serve as the Director of Clinic Operations in Florida post-acquisition.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed a binding Letter of Intent to acquire a majority interest in Neurospa TMS Holdings. Neurospa operates six interventional psychiatry clinics in Florida and provides advanced treatments like TMS and ketamine therapy for severe depression and related conditions. The acquisition aims to enhance HOPE's revenue and expand its psychiatry network. However, the deal depends on meeting standard financial and regulatory conditions.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
NRx Pharmaceuticals reported substantial advancements in its fourth quarter and full-year financial results for 2024, highlighting the initiation of a New Drug Application for NRX-100 aimed at treating suicidal depression. The company has also accepted terms from a commercial partner for the licensing of this drug, with an earmarked financial potential exceeding $300 million. Additionally, NRx is actively pursuing acquisitions to expand its network of interventional psychiatry clinics while addressing critical patient needs in bipolar depression. The strategic focus includes removing toxic preservatives from ketamine preparations and advancing innovative formulations, although the success of these initiatives hinges on regulatory approval.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025
NRx Pharmaceuticals, Inc. will release its fourth quarter and full year 2024 financial results on March 17, 2025. A corresponding conference call is scheduled for the same day at 8:30 AM ET, where updates on the company’s corporate status will also be discussed. The company is developing therapeutics targeting central nervous system disorders and plans to file for NDA Accelerated Approval for its drug NRX-101. The announcement also includes a reminder of the uncertainties associated with future performances.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
NRx Pharmaceuticals, Inc. will present at the Oppenheimer 35th Annual Healthcare Conference and participate in the BIO CEO & Investor Conference, aimed at engaging investors in its clinical developments. CEO Jonathan Javitt is scheduled to share company updates during the presentation on February 12. NRx is focused on innovative treatments for central nervous system disorders and has received Breakthrough Therapy designation for NRX-101. The company also highlights its collaboration with HOPE Therapeutics to expand its therapeutic offerings.
Read more →NRXPHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has engaged BTIG as its financial advisor to support its plan of establishing a global network of interventional psychiatry clinics. This initiative aims to combine various therapeutic approaches for treating severe depression and PTSD. The engagement follows an agreement for $27 million in funding, which will contribute to the acquisition of these clinics and the expansion of their services. Both companies express optimism about addressing the pressing mental health crisis through this collaboration.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt
NRx Pharmaceuticals, Inc. has entered a binding agreement for an $8.9 million financing round involving equity and senior secured debt. The funds are earmarked for filing New Drug Applications for its lead products, NRX-100 and NRX-101, as well as for launching HOPE Therapeutics. This financing is expected to sustain the company’s operations until 2026, furthering its goal to achieve profitability. Institutional investors show confidence in the company's potential, as highlighted by their participation in this funding round.
Read more →NRXPHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has executed a $27 million funding transaction for the acquisition of interventional psychiatry clinics. The deal includes immediate funding of $2 million in NRx stock, with an additional $25 million in Series A Preferred Stock expected to close by April 1, 2025. This funding will be used to roll out a nationwide strategy to treat severe depression and PTSD through innovative therapies, including ketamine and TMS. The company is aiming for up to $100 million in revenue by the end of 2025 as it expands its clinical network.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement
NRx Pharmaceuticals, Inc. has successfully regained compliance with the Nasdaq minimum market value of listed securities requirement, receiving notice from Nasdaq that the matter is now closed. Previously, the company had been notified of non-compliance due to failing to maintain a minimum market value for 30 consecutive trading days. The stock has now maintained the required market value for 10 consecutive days, affirming the company's eligibility to remain listed on the Nasdaq Capital Market.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.
NRx Pharmaceuticals has announced the appointment of Michael Taylor to its Board of Directors and Anita Nunes as a Board Observer, who will also serve on the Board of HOPE Therapeutics, Inc. Taylor brings over 25 years of experience in global credit markets, while Nunes has a strong background in healthcare innovation and strategic investments. Their appointments are anticipated to enhance both NRx’s financial strategies and HOPE Therapeutics' mission in mental health care. NRx, a clinical-stage biopharmaceutical firm, is focusing on developing treatments for central nervous system disorders.
Read more →NRXPHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. have alerted investors about Dr. David Feifel's feature on a CNN program discussing ketamine. Feifel, the founder of Kadima Neuropsychiatry Institute, is set to become the Chief Medical Innovation Officer for HOPE following the acquisition of Kadima. The deal is expected to advance the company's focus on interventional psychiatry treatments and improving patient access to innovative therapies. This initiative aligns with HOPE's mission to develop a network of clinical centers dedicated to psychiatric excellence.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market
NRx Pharmaceuticals (NASDAQ: NRXP) has submitted an application to uplist its shares from the NASDAQ Capital Market to the NASDAQ Global Market. The decision is aimed at improving shareholder liquidity and attracting institutional investment. To qualify, the company needs to achieve a market value above $75 million and maintain a minimum bid price of $4.00 for 90 consecutive trading days. NRx continues to focus on developing treatments for suicidal depression and PTSD, with ongoing efforts to file for regulatory approval for their lead product, NRX-101.
Read more →NRXPHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club
HOPE Therapeutics and NRx Pharmaceuticals recently held an investor workshop at the Mar-A-Lago Club to discuss the expansion of psychiatric clinics targeting suicidal depression and PTSD. The event attracted qualified institutional buyers, resulting in a $25 million financing commitment from Smith and Sauer, aimed at securing $100 million in projected revenue. Future plans include significant expansion of clinic openings and integration of innovative technologies. NRx is also poised for further discussions, with an expanded meeting scheduled for January 2025.
Read more →NRXPHOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
HOPE Therapeutics and NRx Pharmaceuticals announced that Dr. Jonathan Javitt and Dr. David Feifel will present a keynote address on innovative treatments for suicidal depression and PTSD at the Neuroscience Innovation Forum in January 2025. They will discuss the integration of ketamine with other therapies like Transcranial Magnetic Stimulation (TMS) to improve treatment outcomes. NRx has recently initiated the filing of a New Drug Application (NDA) for NRX-100, an IV ketamine treatment for suicidal depression, supported by $27 million in anticipated funding for HOPE's expansions.
Read more →NRXPHOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is hosting an investor workshop for Qualified Institutional Investors in January 2025. The event aims to discuss planned acquisitions for a national network of interventional psychiatry practices focusing on treatments for suicidal depression and PTSD. The company has announced its strategy to integrate clinics that are expected to generate significant revenues and provide advanced treatment options, such as ketamine therapy and TMS. Key executives will provide updates and answer questions during the workshop.
Read more →NRXPHope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics
NRx Pharmaceuticals, through its subsidiary HOPE Therapeutics, has announced the acquisition of Kadima Neuropsychiatry Institute, which will serve as the flagship clinic for an international network focusing on interventional psychiatry. Kadima is notable for its pioneering treatments in mental health, including Ketamine Therapy for conditions such as depression and PTSD. The founder of Kadima, Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer, furthering advancements in therapeutic techniques. The acquisition is set to positively impact NRx's revenue and EBITDA immediately upon completion.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
NRx Pharmaceuticals has submitted the initial section of its New Drug Application (NDA) to the FDA for NRX-100, an intravenous ketamine treatment for suicidal depression. This medication aims to address the urgent needs of over 13 million Americans who consider suicide each year. The completion of the NDA filing is expected in early 2025, with the company confident in the efficacy of NRX-100 based on clinical trial data. NRx received Fast Track Designation in 2017 for ketamine's use in this context, underlining its potential as a new treatment option.
Read more →NRXPNRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets
NRx Pharmaceuticals (NASDAQ: NRXP) announced that Dr. Jonathan Javitt will present at NobleCon20 on December 3, 2024. The presentation will be available via high-definition video webcast the following day. NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, including its investigational drugs NRX-101 and NRX-100, which target serious mental health conditions with breakthrough designations from the FDA.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"
NRx Pharmaceuticals announced the publication of a paper detailing their innovative training and monitoring methodology that enhances reliability in depression ratings, yielding higher interrater reliability in recent clinical trials for NRX-101. This approach, documented in the American Journal of Clinical Psychopharmacology, indicates significant improvements in trial outcomes, which could lead to better drug approvals. The study's findings suggest that fewer participants are now needed to achieve statistical significance, thus reducing costs and risks associated with clinical trials. NRx plans to utilize this improved methodology in future drug development.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer
NRx Pharmaceuticals has appointed Michael Abrams as its new Chief Financial Officer, succeeding interim CFO Richard Narido. Abrams brings nearly three decades of financial leadership experience in the biotechnology field, which the company believes will support its goal of becoming profitable. Narido will continue to aid in the company's financial functions and the acquisition opportunities for HOPE Therapeutics. This leadership change comes at a pivotal time as NRx aims to advance its product developments and navigate critical operational challenges.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals reported its third quarter and year-to-date financial results for 2024. The company is on track to file New Drug Applications for NRX-100 and NRX-101 by the end of the year, aiming to address critical needs in treating suicidal ideation and bipolar depression. Notably, a 74% reduction in net operating losses compared to the previous year highlights improving financial health. The company anticipates its first revenue streams from its subsidiary, HOPE Therapeutics, by the end of 2024, with a profitability forecast for 2025.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024
NRx Pharmaceuticals has announced a rescheduling of its conference call to discuss third quarter and year-to-date 2024 financial results to November 18, 2024. The change aims to accommodate any additional corporate news that may arise. The company is actively developing treatments for mental health disorders through its NMDA platform, with key candidates like NRX-101 and NRX-100 receiving FDA designations for breakthrough therapies.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024
NRx Pharmaceuticals, Inc. announced it will release its financial results for the third quarter and year-to-date 2024 on November 14, 2024. The company will also host a conference call that day to discuss these results and provide a corporate update. NRx is actively developing therapeutics targeting central nervous system disorders, with potential for significant FDA approvals in the near future.
Read more →NRXPNRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule
NRx Pharmaceuticals is set to appear at the Emerging Growth Conference on October 31 in response to investor demand. The company's founder, Dr. Jonathan Javitt, will discuss its acquisition strategies and advancements through its subsidiary, HOPE Therapeutics, focusing on treatments for suicidal depression and PTSD. The presentation will highlight the innovative therapies being developed, including ketamine and transcranial magnetic stimulation. This opportunity underscores NRx's commitment to growth in the mental health sector, particularly targeting severe psychiatric conditions.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. announced the signing of a non-binding Letter of Intent for acquiring their first Interventional Psychiatry Clinics in Florida. These clinics are noted for their strong performance, being revenue generating and EBITDA positive, which is expected to benefit both companies immediately. This acquisition is part of HOPE's strategy to establish a robust network of clinics aimed at providing advanced care in mental health services across the nation. The leadership expressed enthusiasm about optimizing further acquisitions to expand their operations.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will participate in the ThinkEquity Conference on October 30, 2024. Jonathan Javitt, MD, will present at the event, which aims to connect investors and industry professionals. NRx is focused on developing therapies for central nervous system disorders and plans to file an NDA for its investigational drug NRX-101.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
HOPE Therapeutics, Inc. has announced a non-binding Letter of Intent to acquire a leading West Coast Interventional Psychiatric Clinic. The clinic, known for its advanced treatments for CNS disorders, will act as a model for the future network of HOPE clinics across the U.S. As part of the acquisition, the clinic's founder will become the Chief Medical Innovation Officer, aiding in the standardization of care. This strategic move is expected to enhance revenue and EBITDA for both HOPE and NRx Pharmaceuticals.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
NRx Pharmaceuticals has achieved a significant milestone by completing twelve months of stability testing for its NRX-100 (Ketamine) formulation. This preservative-free version is aimed at treating suicidal depression and has shown no degradation, supporting its upcoming FDA New Drug Application submission. The company acknowledges this achievement as a critical step in its drug approval process, with the potential to aid millions of individuals at risk of suicide in the United States.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
NRx Pharmaceuticals, Inc. has been featured on Psychiatrist.com regarding its innovative treatments for bipolar depression and suicidal ideation. The article emphasizes the efficacy of NRX-101, a combination treatment, and NRX-100, an IV ketamine formulation, both of which aim to address serious mental health issues. NRx has received Fast Track Designation for NRX-100, and plans to submit a New Drug Application based on promising clinical trial results. This recognition highlights the company's commitment to improving outcomes for individuals experiencing severe depressive symptoms and suicidality.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
NRx Pharmaceuticals, Inc. and its subsidiary, HOPE Therapeutics, Inc., will participate in the H.C. Wainwright 26th Annual Global Investment Conference scheduled from September 9-11, 2024. The event will feature NRx's Chairman and Chief Scientist, Jonathan Javitt, who will present an overview of the company's business. This conference includes both in-person and virtual presentations, demonstrating NRx's commitment to engage with institutional investors regarding its clinical developments, including therapies for suicidal bipolar depression and chronic pain.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, has announced a potential acquisition and financing agreements totaling $30 million to establish interventional psychiatry clinics in the Western United States. The clinics are expected to generate more than $10 million in annual revenue, with projections of reaching $100 million by mid-2025 as additional partners are included. The company plans to expand operations not only in the U.S. but also in France and the U.K. More details are to be shared at the upcoming HC Wainwright Annual Global Investment Conference in September 2024.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals has reported its financial results for the second quarter of 2024 and outlined significant progress towards FDA New Drug Applications for NRX-100 and NRX-101. The company has secured between $10.8 million to $16.3 million in convertible debt funding, which aims to support regulatory submissions and retire existing debt. Positive clinical trial results demonstrate NRX-100's effectiveness in treating suicidal depression, while NRX-101 shows promise in managing bipolar depression with improved safety. Additionally, NRx has completed the audit of its subsidiary HOPE Therapeutics and plans to spin it out as a separate entity.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
NRx Pharmaceuticals, Inc. is set to report its financial results for the second quarter and year to date 2024 on August 14, 2024, following market closure. The company will also host a conference call for discussing results and updates. NRx is developing therapeutics targeting central nervous system disorders, including treatments for bipolar depression and chronic pain, and has received breakthrough therapy designation for its investigational drugs.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds
NRx Pharmaceuticals, Inc. has announced the acquisition of up to $16 million in senior secured debt financing from Anson Funds. The proceeds from this financing will be utilized to facilitate the 2024 filing of New Drug Applications for NRX-100 and NRX-101, and to retire certain existing debts. The company's Chairman expressed optimism about the partnership and the potential impact of the drugs on patients with suicidal depression. The financing deals include a 6% interest rate and convertible options to equity.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)
NRx Pharmaceuticals, Inc. has received a response from the FDA affirming the proposed Pediatric Study Plan for NRX-100, aimed at treating suicidal depression in adolescents aged 9-17. This alignment is a significant prerequisite prior to the upcoming submission of a New Drug Application planned for Q4 2024, with an anticipated review date of Q2 2025. The FDA's recognition of the increasing prevalence of suicidal depression in youth underscores the urgency of NRx's mission. The company will conduct necessary trials following initial adult approvals to validate the drug's safety and efficacy in the younger population.
Read more →NRXPHOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff
NRx Pharmaceuticals has announced a favorable arbitration ruling permitting the spinoff of 49% of HOPE Therapeutics shares to its shareholders. The decision follows a petition by Streeterville Capital seeking to block the spinoff, which was denied by a Utah arbitrator. The spinoff represents an opportunity for NRx shareholders to partake in the anticipated value created by HOPE Therapeutics. The plan aligns with NRx's strategy to enhance its operational financing and pursue potential listing opportunities for HOPE.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
NRx Pharmaceuticals has released a Shareholder Update Letter outlining potential revenue pathways towards profitability by 2025. The company identifies significant opportunities through its subsidiaries, including anticipated revenue from the operation of HOPE Therapeutics clinics and potential sales from its drug NRX-100, which is pending FDA approval. Additionally, there are optimistic projections for NRX-101 aimed at treating patients with suicidal bipolar depression. The update suggests a proactive approach to engage shareholders and keep them informed on the company's progress.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing
NRx Pharmaceuticals is set to proceed with two New Drug Applications in 2024 for its investigational drugs NRX-101 and NRX-100, targeting bipolar depression and suicidal depression, respectively. The applications are based on positive clinical trial results and the drugs have received regulatory designations such as Breakthrough Therapy and Fast Track. The anticipated revenue from these drugs could exceed $150 per share in the near term, reflecting a significant market opportunity. The company is also progressing towards a public listing of its subsidiary, HOPE Therapeutics.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
NRx Pharmaceuticals, Inc. has announced its participation in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference scheduled for June 27, 2024. Dr. Jonathan Javitt, the company's Chairman and Chief Scientist, will partake in a fireside chat and other meetings with investors during the event. NRx is focused on developing therapeutics for central nervous system disorders, notably their investigational drug NRX-101, which is designated as a Breakthrough Therapy by the FDA. The company's strategy includes submitting a New Drug Application for HTX-100, an IV ketamine treatment for suicidal depression.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors Dr. Dennis McBride brings extensive experience in Neuroscience and its interface wi
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, has appointed Dr. Dennis McBride to its Board of Directors. Dr. McBride brings significant expertise in Neuroscience and Medical Technology, which the company believes will be critical for the development of advanced treatments. The appointment is seen as timely for NRx as it aims to enhance its strategy and expand its pipeline of central nervous system products, particularly in digital therapeutics. Dr. McBride's previous successful endeavors in the field add to the optimism surrounding this leadership change.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression
NRx Pharmaceuticals presented its Phase 2b/3 trial results for NRX-101 at the American Society of Clinical Psychopharmacology Annual Meeting. The study demonstrated that NRX-101 effectively reduces suicidality and akathisia in adults with bipolar depression compared to lurasidone, the current standard of care. Findings indicate a significant reduction in time to sustained remission from suicidality and a decreased incidence of akathisia symptoms. The company aims to progress NRX-101 through the registration trial process to make it available to patients in need.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update 2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in
NRx Pharmaceuticals reported strong financial results for Q1 2024, highlighting successful clinical data for NRX-101 in suicidal bipolar depression. The company is planning to file New Drug Applications (NDAs) for NRX-101 and IV Ketamine by mid-2024, targeting significant unmet needs in mental health and pain management. NRx is working with partners for the final development of NRX-101 while navigating regulatory challenges and market pressures. The FDA has granted QIDP designation for NRX-101 related to urinary tract infections, further validating its therapeutic potential.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
NRx Pharmaceuticals, Inc. is set to participate in the EF Hutton Annual Global Conference on May 15, 2024, in New York City. Key company executives, including Prof. Jonathan Javitt and Matthew Duffy, will engage in one-on-one discussions with investors. NRx is focused on developing therapeutics for central nervous system disorders, with notable products like NRX-101 and HTX-100 aimed at treating suicidal bipolar depression and chronic pain. The company holds FDA breakthrough designations for its investigational therapies.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
NRx Pharmaceuticals, Inc. will announce its first quarter 2024 financial results on May 14, 2024, after market closure. The announcement will be followed by a conference call to discuss these results and provide a corporate update. The company continues to develop its NMDA platform for treating various central nervous system disorders, including its leading candidate NRX-101, which is designated as an investigational Breakthrough Therapy by the FDA. Additionally, NRx is planning to submit a New Drug Application for HTX-100 based on promising clinical trial results.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
NRx Pharmaceuticals announced the final results of its clinical trial for NRX-101, which demonstrated a significant safety advantage over lurasidone in patients with suicidal bipolar depression. NRX-101 had a much lower rate of akathisia, a serious side effect associated with increased suicide risk, occurring in only 2% of participants compared to 11% for lurasidone. The company plans to seek accelerated FDA approval for NRX-101 based on these findings, which may also support further indications for depression treatment. The full trial results will be presented at the upcoming ASCP meeting in Miami.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
NRx Pharmaceuticals, Inc. has announced the pricing of its underwritten public offering, setting the share price at $3.30 and expected to raise approximately $2.0 million. The offering is scheduled to close on April 19, 2024, pending customary closing conditions. The company plans to utilize the proceeds for working capital, general corporate purposes, and potentially repaying certain debts. EF Hutton LLC serves as the sole book-runner for this offering.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
NRx Pharmaceuticals has received confirmation from Nasdaq of its compliance with bid price requirements, allowing its securities to remain listed. The company anticipates significant upcoming milestones, including data releases for treatments related to suicidal bipolar depression and chronic pain, as well as a New Drug Application for intravenous ketamine. Additionally, NRx Pharmaceuticals has seen recent advances that may expand its treatment capabilities, potentially benefiting shareholders significantly.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock RADNOR, Pa.
NRx Pharmaceuticals has announced its intention to undertake an underwritten public offering of common stock, aiming to use the proceeds for corporate purposes including a national treatment protocol. The offering is subject to market conditions, and its size and terms are not guaranteed. EF Hutton LLC will act as the sole book-running manager for this offering. The company is focused on developing therapeutics for central nervous system disorders, with plans for new drug applications in progress.
Read more →NRXPNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
NRx Pharmaceuticals announced that new data indicates NRX-101 does not adversely affect intestinal or vaginal flora in rodent models, suggesting it may avoid common antibiotic side effects linked to C. difficile infections. This drug has already received FDA Qualified Infectious Disease Product and Fast Track Designations for treating complicated urinary tract infections (cUTI) and pyelonephritis. The findings, if replicable in humans, could position NRX-101 as a groundbreaking solution in a multi-billion-dollar market for conditions affected by conventional antibiotics. Experts emphasized its potential to transform treatment paradigms for cUTI patients in the U.S.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
NRx Pharmaceuticals announced the development of a novel pH neutral formulation of IV Ketamine, known as HTX-100. This formulation aims to enhance administration methods, including potential use in insulin pump devices, thereby reducing the complexity of outpatient procedures. The company anticipates securing patent protection for this innovative formulation, which may lead to significant advancements in treatment for conditions like suicidal depression. Collaborating with Nephron Pharmaceuticals, NRx is approaching the market with a formulation optimized for modern medical use.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals has achieved data-lock for its Phase 2b/3 trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression, with top-line data expected in April 2024. Successful outcomes could lead to a potential market expansion from hundreds of thousands to millions of patients. The drug is notable for its FDA designations, and NRx is on track to secure significant milestone payments from partners. This trial marks a first-of-its-kind effort to include suicidal patients in clinical trials for oral therapies.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Four potential near-term milestones, including data from two clinical trials, an NDA filing and a
NRx Pharmaceuticals reported positive financial results for Q4 and the full year 2023, marking a significant operational improvement with a reduction in corporate overhead and net losses. The company announced several potential near-term milestones, including the expectation of first commercial revenue in 2024 and advancements in clinical trials of NRX-101, a treatment for Treatment-Resistant Bipolar Depression. Partnerships with Alvogen and Lotus Pharmaceuticals have bolstered the company’s financial stability, and new FDA approvals have been secured to develop NRX-101 for additional indications including chronic pain and complicated urinary tract infections. Management remains optimistic about substantial growth in upcoming quarters despite ongoing challenges in the biotech landscape.
Read more →NRXPNRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing Common Stock Will Begin Trading on Split-Adjusted Basis on
NRx Pharmaceuticals announced a reverse stock split of 1-for-10 to maintain compliance with Nasdaq listing requirements, effective April 1, 2024. This measure aims to position the company favorably for institutional investors and enhance long-term shareholder value. The split will reduce the number of outstanding shares and is coupled with anticipated clinical trial data releases for treatments in suicidal bipolar depression and chronic pain. The company also plans to submit a New Drug Application for ketamine in the near future.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
NRx Pharmaceuticals reported its preliminary financial results for the fourth quarter and full year of 2023, noting an improvement in negative earnings per share. The company anticipates a positive cash flow by the end of 2024, aided by partnerships and ongoing trials. Key milestones include the conclusion of the Phase 2b/3 trial for NRX-101, acceptance of new INDs by the FDA, and significant funding efforts for its specialty pharmaceutical subsidiary, HOPE Therapeutics. These advancements could position NRx for substantial growth in 2024.
Read more →NRXPUPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NRx Pharmaceuticals has announced that it will release its fourth quarter and full year 2023 financial results on March 28, 2024. The company has rescheduled its conference call for April 1, 2024, to discuss these results and provide a corporate update. NRx is recognized for developing therapeutics for central nervous system disorders, particularly targeting treatment-resistant bipolar depression and chronic pain. Their lead candidate, NRX-101, has received Breakthrough Therapy designation from the FDA, reflecting its potential significance in mental health treatment.
Read more →NRXPNRx Pharmaceutical
NRx Pharmaceuticals announced that Dr. Jonathan Javitt will present at the Ketamine 2024 Conference, focusing on the efficacy and risks of Ketamine in treating acute suicidality. This follows the company's development of NRX-101, which has received Breakthrough Therapy designation from the FDA for suicidal treatment-resistant bipolar depression. The presentation will highlight the critical balance between Ketamine's rapid efficacy and its associated risks, including potential neurotoxicity. NRx aims to submit a New Drug Application for HTX-100 based on promising clinical trial results.
Read more →NRXPNRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
NRx Pharmaceuticals, Inc. has announced the release of its fourth quarter and full year 2023 financial results on March 28, 2024. The company will provide a corporate update during a conference call scheduled for 4:30 p.m. ET the same day. NRx is focused on developing therapeutics for central nervous system disorders, with NRX-101 and HTX-100 being notable candidates. NRX-101 has been designated as a Breakthrough Therapy by the FDA, and the company is preparing to submit a New Drug Application for HTX-100 based on positive clinical trial results.
Read more →NRXPNRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders 61.4% (56,781,354) of eligible shares voted 94.4% of votes were cast in favor of the resolution RADNOR, Pa.
NRx Pharmaceuticals announced the results of the Special Meeting of Shareholders, where 61.4% of eligible shares voted, with 94.4% in favor of a reverse stock split proposal. The resolution grants the Board of Directors the authority to determine the split ratio between 1-for-2 to 1-for-15 at a later date. The company's leadership expressed gratitude for shareholder support amid challenges from detractors. Looking ahead, NRx plans to share its annual report on March 28 and provide updates on ongoing projects.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
NRx Pharmaceuticals (NASDAQ:NRXP) has announced plans to distribute shares of HOPE Therapeutics and royalty rights on Ketamine sales to its shareholders. The Board authorized the distribution of 49% of HOPE stock along with a 1% royalty on Ketamine sales, reflecting the company's commitment to enhancing shareholder value. Additionally, HOPE Therapeutics aims to advance an IV Ketamine product towards a New Drug Application filing, which may positively impact its market position in the near term. Proxy voting for this initiative is set to be concluded by March 20, 2024.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
NRx Pharmaceuticals has initiated a strategy to combat shortseller activity by proposing a change in its corporate name to NRx Therapeutics, along with a potential reverse stock split. This initiative seeks to maintain compliance with Nasdaq listing rules and address issues related to naked short sales. The company has engaged former SEC leaders to notify brokerages about the need to close these positions. NRx is also focused on the development of its therapeutics for mental health conditions and chronic pain.
Read more →NRXPNRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
NRx Pharmaceuticals has finalized a Memorandum of Understanding with Conversio Health and established a partnership with Nephron Pharmaceuticals for the distribution of IV Ketamine. The company anticipates the first allocation to be available for sale by the end of March 2024. This collaboration aims to provide various supply options for ketamine, with plans for an NDA filing for HTX-100 in the near future, potentially launching by early 2025. These developments represent significant progress towards supplying high-quality ketamine products for patients in need.
Read more →NRXPNRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals has announced the completion of the last patient visit in its Phase 2b/3 trial of NRX-101 for suicidal treatment-resistant bipolar depression. The database is being cleaned and statistical analysis will follow, with top-line results expected shortly. The trial maintained a high concordance rate on primary endpoints, and no serious adverse events were reported. Positive outcomes could trigger milestone payments from Alvogen, who will take over further development upon positive data release.
Read more →NRXPNRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
NRx Pharmaceuticals has entered into a definitive purchase agreement to sell approximately 2.7 million shares of common stock at $0.38 each, alongside warrants for the same number of shares at a $0.40 strike price. This transaction is expected to generate around $1.0 million in funding, which will support the company's development pipeline, particularly in treating Suicidal Depression and Chronic Pain. The share price reflects a 26.7% premium over their most recent offering, indicating strong investor interest despite challenging market conditions.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock
NRx Pharmaceuticals, Inc. has announced the pricing of a public offering of common stock, set at $0.30 per share, with gross proceeds expected to reach approximately $1.5 million. The offering includes a 45-day option for underwriters to purchase additional shares to cover over-allotments. Proceeds from the offering will be used for working capital, general corporate purposes, and to service current debt obligations. The offering is scheduled to close on February 28, 2024, pending customary conditions.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
NRx Pharmaceuticals has launched HOPE Therapeutics, a subsidiary aimed at developing intravenous ketamine treatments for acute suicidality and depression. During the BIO CEO & Investor Conference, company leaders proposed to allocate 50% of founding shares in HOPE Therapeutics to current shareholders, contingent on board approval. HOPE plans to manufacture ketamine supplies by July 1, 2024, and is pursuing partnerships to facilitate its research and sales efforts. The initiative emphasizes integrating a digital therapeutic platform alongside ketamine offerings to improve clinical outcomes for patients.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW) Companies continue to work collaboratively to advance NRX
NRx Pharmaceuticals has reported the advancement of a $5 million milestone payment from its partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. This funding will be utilized to support the development of NRX-101, targeted for treating bipolar depression with suicidality. Additionally, the agreement allows for NRx to potentially earn up to $320 million in future milestones and royalties. The collaboration underlines a strong partnership aimed at addressing important therapeutic needs in mental health.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that it has completed enrollment for its pivotal phase 2b/3 trial of NRX-101 aimed at treating suicidal treatment-resistant bipolar depression. This significant milestone was highlighted by their strategic partner, Lotus Pharmaceutical Co. Ltd, in a recent financial report. The trial's results are expected in the second quarter of 2024, showing a collaborative effort to address a critical mental health issue. NRx's CEO emphasized the importance of the partnership in delivering a lifesaving treatment to patients who have limited options.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon
NRx Pharmaceuticals, Inc. has announced the incorporation of HOPE Therapeutics, which will focus on the commercialization of NRX-100, a treatment for suicidal depression. Shareholders will receive a dividend and royalty coupon, pending Board approval, as part of this initiative. A New Drug Application for NRX-100 is anticipated in the first half of 2024. However, the company has canceled the planned shareholder meeting, which could reflect uncertainties in corporate decision-making.
Read more →NRXPNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination RADNOR, Pa.
NRx Pharmaceuticals, Inc. announced that it received a positive determination from the Nasdaq Hearings Panel for transferring its listing to the Nasdaq Capital Market. The company believes it meets the market value requirement and is working towards compliance with bid price requirements by April 2024. NRx aims to file a New Drug Application for NRX-100 for suicidal depression and will soon announce results from its phase 2b/3 trial of NRX-101 for suicidal bipolar depression. The announcement reflects the company's commitment to meeting drug development milestones.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard
NRx Pharmaceuticals (Nasdaq: NRXP) has announced its plan to achieve compliance with Nasdaq market requirements after previously receiving deficiency notices regarding minimum bid price and market value. The company successfully demonstrated compliance with the minimum market value of listed securities (MVLS) of $35 million and aims to maintain this moving forward. NRx plans to present its compliance strategy to Nasdaq on January 4, 2024, and is focusing on reaching clinical and regulatory milestones. Additionally, the company has several drug candidates in advanced stages that show promising commercial potential.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco
NRx Pharmaceuticals will present a keynote on ketamine's efficacy and risks at the upcoming Sachs Neuroscience Innovation Forum. The company plans to submit a New Drug Application for ketamine targeting suicidal depression in 2024. Recent trials suggest ketamine outperforms placebo and matches electroshock therapy's effectiveness. NRx is developing a modern formulation and partnering with psychiatry leaders to ensure safe application in clinical settings.
Read more →NRXPNRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
NRx Pharmaceuticals has announced the election of Janet Rehnquist to its Board of Directors. Rehnquist, a former Inspector General of the U.S. Department of Health and Human Services and an experienced healthcare attorney, will chair the compliance and nominating committees. Her background aligns well with NRx's mission to develop treatments for psychiatric disorders, particularly for suicidal depression. The company is actively pursuing innovative drug therapies, including NRX-101, which is designated as a Breakthrough Therapy by the FDA.
Read more →NRXPNRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
NRx Pharmaceuticals has announced the FDA's approval of its Investigational New Drug (IND) application for NRX-101, a treatment intended for complicated urinary tract infections (cUTI). This drug combines D-cycloserine and lurasidone to tackle antibiotic-resistant pathogens affecting millions of Americans. With manufacturing complete and patent protection secured, the company plans to advance to clinical trials in 2024 without requiring further funding. They await FDA feedback regarding a request for Qualified Infectious Disease Product designation, which could enhance the development pathway.
Read more →NRXPNRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders
NRx Pharmaceuticals will hold its 2023 Annual Meeting of Stockholders on December 19, 2023, in a virtual format. Key agenda items include the election of Janet Rehnquist to the Board, a highly respected attorney with extensive experience in healthcare. The company also plans to discuss the forthcoming spinoff of Hope Therapeutics, which will focus on IV Ketamine treatments. NRx Pharmaceuticals is actively developing therapies for central nervous system disorders and aims to submit a New Drug Application for ketamine based on recent clinical trial data.
Read more →NRXPNRx Pharmaceuticals to Participate in LifeSci Corporate Access Event
NRx Pharmaceuticals, Inc. will participate in the LifeSci Partners Corporate Access Event from January 8-10, 2024, in San Francisco. The company plans to update investors on its progress towards filing its first New Drug Application and has four near-term projects that could lead to significant financial returns. Notably, NRX-100 and NRX-101 are being developed for key mental health issues and chronic pain, with important data readouts expected in early 2024. NRx also has potential partnerships and licensing opportunities on the horizon.
Read more →NRXPNRx Pharmaceuticals to Present at Noble Capital Markets
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its Founder and Chief Scientist, Dr. Jonathan Javitt, will present a corporate overview at the Noble Capital Markets' 19th Annual Emerging Growth Investor Conference on December 4th, 2023, in Boca Raton, Florida. The event will include in-person one-on-one meetings and a presentation. NRx is focused on developing therapeutics for central nervous system disorders and has received FDA designations for some of its treatments. An archived replay of the presentation will be available on their website afterward.
Read more →NRXPNRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enroll
NRx Pharmaceuticals announced its financial results for the third quarter of 2023 and provided updates on key clinical initiatives. The company approaches critical milestones for its NRX-101 product, including expanded clinical trials for chronic pain and treatment-resistant bipolar depression. Significant advancements in partnerships and funding are anticipated, particularly with the Department of Defense and commercial partners. NRx is optimistic about the potential impacts on shareholder value as it continues to progress through planned trials and regulatory processes.
Read more →NRXPNRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023
NRx Pharmaceuticals is set to release its third quarter 2023 financial results on November 14, 2023, accompanied by a corporate update and a conference call. The anticipated results will cover the development of NRX-101 for bipolar depression, chronic pain, and other indications, along with the timing of clinical trial data. A live webcast of the conference call will also be available for participants, reflecting the company's commitment to transparency and stakeholder engagement.
Read more →NRXPNRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression
NRx Pharmaceuticals and Nephron Pharmaceuticals have formed a joint agreement to develop an intravenous formulation of ketamine aimed at treating suicidal depression. With no current FDA-approved ketamine formulation for this purpose, the partners plan to submit a New Drug Application by March 2024, targeting to have a finished drug ready by November 2024. This collaboration comes in response to alarming statistics regarding suicide, and if successful, it could offer a lifesaving option for patients facing mental health crises.
Read more →NRXPNRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support Industry veteran Richard Narido joins the NRx Pharmaceuticals management team RADNOR, Pa.
NRx Pharmaceuticals has entered into an agreement with LifeSci Associates for financial consulting services, appointing Richard Narido as the Interim Chief Financial Officer. Narido brings extensive experience from his previous role at Lucira Health and other positions in the biopharmaceutical industry. The transition follows the resignation of former CFO, Seth Van Voorhees, as he seeks new opportunities. NRx is also exploring the potential of their lead product, NRX-101, which received Breakthrough Therapy Designation from the FDA for treating severe bipolar depression.
Read more →NRXPNRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NRx Pharmaceuticals announced that CEO Stephen Willard and Chief Scientist Dr. Jonathan Javitt will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. The company will discuss NRX-101, a lead product that has received multiple FDA designations for treatment-resistant bipolar depression. NRX-101 aims to establish itself as a non-opioid treatment for chronic pain and PTSD. The conference includes opportunities for one-on-one meetings and will feature a live webcast of the presentation.
Read more →NRXPNRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens
NRx Pharmaceuticals announced promising results for NRX-101, a drug demonstrating strong antibacterial effects against antibiotic-resistant urinary pathogens. The compound, an oral combination of D-cycloserine and lurasidone, may provide an effective treatment for complicated urinary tract infections (cUTIs) amidst rising antibiotic resistance. The FDA has granted both Fast Track and Breakthrough Therapy Designations for NRX-101, positioning the company to seek investigational human use for this indication while also pursuing applications in bipolar depression and chronic pain.
Read more →NRXPNRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
NRx Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for NRX-101, aimed at treating chronic pain. This application builds on earlier studies suggesting the drug's efficacy, particularly through its active ingredient, D-cycloserine. The company plans to seek additional designations to expedite development, citing a significant need for non-addictive pain management options. NRx's expansion of NRX-101 beyond bipolar depression reflects its potential in addressing chronic pain, which is a large and growing market.
Read more →NRXPNRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share NRx Pharmaceuticals received approximately $1.2 million in cash from existing investors Preferred shares to sold at $0.4
NRx Pharmaceuticals announced a definitive purchase agreement to sell 3,000,000 preferred shares at $0.40 each, resulting in $1.2 million in cash from investors. These shares will convert into common stock and warrants after six months. The company is poised to release data from key clinical trials related to Suicidal Bipolar Depression and Chronic Pain during this period. The agreement highlights investor confidence amid a challenging biotechnology capital market, though the lack of registration for the securities raises liquidity concerns.
Read more →NRXPNRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
NRx Pharmaceuticals reported promising financial results and updates on their ongoing clinical programs in their second-quarter report for 2023. They announced a collaboration with Alvogen and Lotus Pharmaceuticals, potentially generating $330 million in milestone payments for the development of NRX-101 in suicidal bipolar depression. The company also highlighted positive results from their STABIL-B trial, which indicated significant benefits of NRX-101 in reducing suicidality compared to current standard treatments, alongside plans to seek FDA approval for chronic pain indications. A data readout from an ongoing Phase 2b/3 trial is anticipated in Q4 2023.
Read more →NRXPNRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain
NRx Pharmaceuticals announced the licensure of US Patent 8,653,120, supporting the use of D-cycloserine in treating chronic pain through its product NRX-101. This patent is backed by nonclinical and early clinical data suggesting the drug's potential in reducing chronic and neuropathic pain while minimizing opioid cravings. The company has also welcomed Dr. Vania Apkarian to its Scientific Advisory Board, enhancing its capabilities in pain research. Notably, NRX-101 is being examined in a confirmatory trial for chronic pain with promising preliminary results.
Read more →NRXPNRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023
NRx Pharmaceuticals, Inc. will announce its second quarter 2023 financial results on August 14, 2023, after market close. A conference call will follow that afternoon to discuss these results and provide updates on their drug NRX-101, which is currently in a Phase 2b/3 clinical trial for treating bipolar depression and related conditions. The company is known for its focus on central nervous system disorders and has previously demonstrated significant improvements in patients with treatment-resistant bipolar depression.
Read more →NRXPNRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger
NRx Pharmaceuticals Inc. is under investigation by Levi & Korsinsky, LLP regarding the fairness of its 2021 de-SPAC merger. The inquiry follows a noticeable decline in NRXP stock shortly after the merger's completion. The firm is scrutinizing whether the transaction harmed shareholders and if all relevant facts were disclosed to them. Investors who purchased stock prior to May 24, 2021, are encouraged to learn more about their rights in this matter.
Read more →NRXPNRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
NRx Pharmaceuticals, Inc. announced that its CEO Stephen Willard and Chief Scientist Dr. Jonathan Javitt will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on June 26, 2023. The presentation will cover the company's advancements and ongoing clinical trials, particularly concerning its lead drug candidate NRX-101 for treating severe bipolar depression. A live webcast and subsequent archived replay of the event will be accessible on the company's website, allowing for broader dissemination of their work.
Read more →NRXPNRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering
NRx Pharmaceuticals announced the closure of its $6.28 million registered direct offering, involving the sale of approximately 9.67 million shares of common stock. In conjunction, the company is issuing unregistered warrants to purchase an equal number of shares. The proceeds from the offering are intended for working capital and to further research into its drug NRX-101, aimed at treating PTSD and Chronic Pain. The offering was facilitated by H.C. Wainwright & Co. and includes significant details about the warrants and existing investment options amendments.
Read more →NRXPNRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering RADNOR, Pa.
NRx Pharmaceuticals has announced a registered direct offering of approximately $6.28 million, which includes the purchase of nearly 9.7 million shares at $0.65 each. Proceeds from the offering will be utilized for working capital and may support new research into NRX-101, aimed at treating PTSD and Chronic Pain. The offering is expected to close on or about June 8, 2023, and comes after the company received FDA Breakthrough Therapy Designation for NRX-101, which is in late-stage clinical studies targeting severe bipolar depression with suicidality.
Read more →NRXPNRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101 - NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development
NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen Inc. have entered a global collaboration to develop and commercialize NRX-101, targeting suicidal treatment-resistant bipolar depression in various markets. This collaboration allows NRx to receive significant financial support upon achieving critical milestones in their clinical development, including an initial payment of $10 million and bonuses based on sales targets. The partnership aims to leverage Lotus's and Alvogen's market presence and experience, potentially bringing a groundbreaking treatment to patients with significant unmet needs in mental health.
Read more →NRXPNRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023
NRx Pharmaceuticals announced its plan to host a corporate and strategic update conference call on June 5, 2023. The call aims to provide insights into the company's ongoing developments, particularly regarding its lead product NRX-101, which targets central nervous system disorders. NRX-101 is currently under investigation in a Phase 2b/3 clinical trial for suicidal treatment-resistant bipolar depression, for which it has gained FDA recognition through a Special Protocol Agreement and Breakthrough Therapy Designation.
Read more →NRXPNRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
NRx Pharmaceuticals announced its first quarter 2023 financial results and provided an update on its clinical efforts, particularly the Phase 2b/3 trial of NRX-101 for Suicidal Treatment-Resistant Bipolar Depression. The company reported an ongoing enrollment push backed by a national campaign and will meet with the FDA to discuss its enhanced regulatory status for the drug. Financially, NRx ended the quarter with $16.5 million in cash, while demonstrating significantly lower research costs compared to the previous year. They plan to expand NRX-101's indications to include PTSD in the near future.
Read more →NRXPNRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call
NRx Pharmaceuticals has rescheduled its first quarter 2023 financial results conference call from May 11 to May 16, 2023, due to scheduling conflicts. The earnings press release will be issued on the morning of May 16, followed by a management-hosted call at 8:30am ET. The company is focused on developing therapies for central nervous system disorders, specifically bipolar depression and PTSD, with its lead program NRX-101 in clinical trials.
Read more →NRXPNRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
NRx Pharmaceuticals, a clinical-stage biopharmaceutical firm, will release its first quarter 2023 financial results on May 11, 2023, after market closure. The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results and provide a corporate update. The webcast of the call will be available on their website, and an archive will be accessible for 30 days post-event. NRx is focused on developing therapies for central nervous system disorders, with its lead program NRX-101 being evaluated in a Phase 2b/3 clinical trial for treating severe bipolar depression.
Read more →NRXPNRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NR
NRx Pharmaceuticals reported its financial results for full year 2022 and provided an update on its business operations. The company reinitiated its psychiatry drug development program and advanced its lead compound, NRX-101, into a Phase 3 trial for treating suicidal treatment-resistant bipolar depression. Notably, the trial includes patients with suicidal ideation, addressing a significant gap in treatment options. However, NRx faces financial challenges, marked by a decrease in total assets and an increase in liabilities, which could pose risks going forward.
Read more →NRXPNRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
NRx Pharmaceuticals has received a positive recommendation from the independent Data Safety Monitoring Board to continue enrolling patients in its ongoing trial of NRX-101 for Suicidal Treatment-Resistant Bipolar Depression. With no reported safety or futility signals in the first 50 patients, the trial is set to be upgraded to a Phase 2b/3 study that could facilitate a future registrational filing. This trial represents a significant opportunity for the approximately 1 million patients in the U.S. suffering from this condition, as there are currently no approved pharmacological treatments available.
Read more →NRXPNRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
NRx Pharmaceuticals announced it will release its fourth quarter and full year 2022 financial results on March 30, 2023. Following the release, there will be a conference call to discuss the results and offer a clinical and corporate update. The company is known for developing therapeutics for CNS disorders, including the promising NRX-101, currently under investigation for bipolar depression and suicidal ideation.
Read more →NRXPAnnounces Close of $2.9 Million Registered Direct Offering
NRx Pharmaceuticals has announced the completion of a $2.9 million registered direct offering, involving 3,766,666 shares and warrants. The funds are intended to support the initiation of a safety database under an FDA expanded access protocol for their lead product, NRX-101, which targets bipolar depression and suicidality. CEO Stephen Willard expressed appreciation for the support from existing investors, treating the investment as a vote of confidence in the company's potential in developing innovative treatments amid a challenging biotech market.
Read more →NRXPNRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering NRx Pharmaceuticals received approximately $2.9 million in cash from existing investors. Offering will assist the Company to initiate its Nat
NRx Pharmaceuticals announced the closure of a $2.9 million registered direct offering, which involved the sale of shares and warrants to existing investors. The capital raised will support the initiation of a safety database under an FDA expanded access protocol for NRX-101, an oral treatment for bipolar depression and related conditions. CEO Stephen Willard highlighted the investors' continued support as a vote of confidence in the company's efforts to develop innovative therapies for mental health disorders. The company plans to leverage these funds for general working capital, including real-world data collection on NRX-101's effectiveness.
Read more →NRXPNRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio
NRx Pharmaceuticals has announced the issuance of a new U.S. patent for its lead formulation NRX-101, aimed at treating bipolar depression with acute and subacute suicidality. This patent adds to the company's expanding portfolio, which now totals 48 issued patents and 42 pending applications worldwide. NRX-101, which has received FDA Breakthrough Therapy Designation, represents a potential breakthrough in neuropsychiatric care, particularly for patients at risk of suicide. The patent is expected to secure the company's intellectual property position until at least 2033, highlighting the ongoing development of innovative treatments in this critical area.
Read more →NRXPNRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality FDA discussed a broader indicati
NRx Pharmaceuticals reported on a recent FDA meeting regarding NRX-101's development for severe bipolar depression and suicidality. The FDA suggested a broader population for the drug's indication, which could expedite the clinical program without delaying ongoing trials. The company is considering expanding its current phase 2 trial in response to FDA guidance and is also planning to augment its safety database. The FDA's input is set to influence NRX Pharmaceuticals' future regulatory strategies and could significantly impact its patient population.
Read more →NRXPNRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
NRx Pharmaceuticals reported positive recommendations from the Data Safety Monitoring Board for its clinical trial of NRX-101, an experimental treatment for Severe Bipolar Depression with subacute suicidal ideation. The Board found no safety concerns among the initial fifty participants and recommended the continuation of trial enrollment. This trial marks a significant step as NRX-101 is specifically designed for a larger outpatient population, addressing an urgent need for effective treatments in this area. The company plans to further assess study data in March 2023 to ensure ongoing safety and evaluate the trial's potential efficacy.
Read more →NRXPNRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
NRx Pharmaceuticals has provided an update on its interactions with the FDA regarding the submission path for its lead compound, NRX-101. The company received a written response from the FDA on January 10, affirming alignment on the manufacturing plan. Additionally, a Type B meeting was held on January 11, with minutes expected in 30 days. NRx-101 is under investigation for treating bipolar depression and acute suicidal ideation, supported by FDA's Breakthrough Therapy Designation.
Read more →NRXPNRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
NRx Pharmaceuticals is set to present a scientific update on its NRX-101 development program for suicidal bipolar depression at the 6th Annual Neuroscience Innovation Forum, coinciding with the 2023 J.P. Morgan Healthcare Conference. This presentation will include insights into the company's Phase 2 and Phase 3 clinical trials. NRX-101 is under investigation as a potential treatment option in patients with suicidal ideation, with FDA support through Breakthrough Therapy Designation. Details from the presentation will be available on NRx's website for interested parties.
Read more →NRXPNRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted
NRx Pharmaceuticals has initiated a Phase 3 clinical trial for NRX-101, aimed at treating Severe Bipolar Depression with Acute Suicidal Ideation and Behavior. This investigational drug holds significant promise as the first targeted treatment for a condition currently limited to electroconvulsive therapy. The trial has received Breakthrough Therapy Designation from the FDA and is supported by a Special Protocol Assessment, indicating a favorable review process. The first trial site has been contracted, with patient dosing anticipated to commence in early 2023, marking a crucial step in addressing this critical mental health issue.
Read more →NRXPNRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs Focused psychiatry practice expert in PTSD, Affective Disorders and Schizophrenia Proven track record in research as an investigator and academic grant-funded research
Read more →NRXPNRx Receives Nasdaq Notice of Listing Compliance
RADNOR, Pa., Dec. 2, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmac
Read more →NRXPNRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Completed a technology transfer, submitted a new manufacturing file to the United States ("U.S.") Food and Drug Administration ("FDA"), and released new drug produced with processes designed to support commercial-stage manufacturing of a Phase 3 investigational drug On track to
Read more →NRXPAd hoc announcement pursuant to Art. 53 LR Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements Geneva, Switzerland and Radnor, Pennsylvania
Ad hoc announcement pursuant to Art. Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements Geneva, Switzerland and Radnor, Pennsylvania, November 14, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) ("Relief"), and
Read more →NRXPNRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022
--Company to Host Conference Call November 14, 2022, at 8:00AM ET--- RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will repor
Read more →NRXPNRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process
Manufacturing files submitted to U.S. Food and Drug Administration The company has now completed its transition to U.S.-based manufacturing NRX-101 is now manufactured via a commercial-stage process RADNOR, Pa., Nov. 9, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: N
Read more →NRXPNRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing
RADNOR, Pa., Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has obtained approximately $11 million in unsecured debt financing (the "Note") fro
Read more →NRXPNRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference
Company to Present Corporate Update During Investor Conference, Sept. 14, 2022, at 9:00am ET RADNOR, Pa., Sept. 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Will
Read more →NRXPRELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION
Relief Therapeutics and NRx Pharmaceuticals, Inc. Release of an ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa., Aug. 22, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (OTCQB: RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NA
Read more →NRXPRelease of an ad hoc announcement pursuant to Art. 53 LR RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION Geneva, Switzerland and Radnor, Pennsylvania
Release of an ad hoc announcement pursuant to Art. RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION Geneva, Switzerland and Radnor, Pennsylvania, August 22, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB:
Read more →NRXPNRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise
Company to Host Conference Call and Webcast August 15, 2022, at 8:30am ET RADNOR, Pa., Aug. 15, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced its financial resu
Read more →NRXPNRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022
--Company to Host Conference Call August 15th, 2022, at 8:30AM ET--- RADNOR, Pa., Aug. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will repor
Read more →NRXPNRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies Proven track recor
Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director RADNOR, Pa., July 13, 2022 /PRNewswire/ - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, today a
Read more →NRXPFDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir
Focus is now on NRX-101 for Bipolar Depression with Suicidality RADNOR, Pa., July 1, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA)
Read more →NRXPNRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
Company to Present Corporate and Psychiatry Franchise Update During Webcast, June 27, 2022, at 7:00am ET RADNOR, Pa., June 23, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced its
Read more →NRXPClass Action Suit Against NRx Pharmaceuticals Dismissed
RADNOR, Pa., June 22, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned "Dal Bosco v. NR
Read more →NRXPNRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)
RADNOR, Pa., June 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), ("NRXP" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) denied the Breakthrough Therapy design
Read more →NRXPNRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer RADNOR, Pa.
Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer Pa., June 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, announced today that the company's Board of Directors appointed Seth
Read more →NRXPNRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI (aviptadil) in Critical COVID-19 Based on a review of nearly 75% of the target enrollm
Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI (aviptadil) in Critical COVID-19 Pa., May 25, 2022 /PRNewswire/ - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stag
Read more →NRXPNRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference
Company to Present Corporate Update During Investor Webcast, May 24, 2022, at 7:00am ET RADNOR, Pa., May 19, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Bes
Read more →NRXPNRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Company to Host Conference Call and Webcast May 16, 2022, at 8:30am ET RADNOR, Pa., May 16, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended
Read more →NRXPNRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality
NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality (not requiring hospitalization). NRX-101 is a patented, fixed dose combinatio
Read more →NRXPNRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022
--Company to Host Conference Call May 16, 2022, at 8:30AM ET-- RADNOR, Pa., May 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report first quarter 2022 f
Read more →NRXPNRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress
Breakthrough Therapy designation was requested based on data from post-hoc analysis of patients who in addition to Aviptadil or placebo were also treated with Remdesivir and whose respiratory failure due to Critical COVID-19 continued to progress. Submission includes cumulative
Read more →NRXPNRx Pharmaceuticals
Company to Present Corporate Update During Investor Webcast, April 14, 2022, at 4:30pm ET RADNOR, Pa., April 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, today announced its interim Chief E
Read more →NRXPNRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results
Company to Host Conference Call and Webcast March 31, 2022, at 8:30am ET RADNOR, Pa., March 31, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, today announced its financial results for the year
Read more →NRXPNRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022
--Company to Host Conference Call March 31, 2022, at 8:30AM ET--- RADNOR, Pa., March 28, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report year end 2021 f
Read more →NRXPNRXP DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 21 Deadline in Securities Class Action – NRXP, NRXPW
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP, NRXPW) between June 1, 2021 and November 4, 2021, inclusive (the “Class Period”), of the importan
Read more →NRXPNRx Pharmaceuticals Appoints Ira Strassberg as Chief Financial Officer and Treasurer RADNOR, Pa.
NRx Pharmaceuticals Appoints Ira Strassberg as Chief Financial Officer and Treasurer RADNOR, Pa., March 18, 2022 /PRNews wire/ - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage pharmaceutical company, announced today that the company's Board of Directors appointed Ir
Read more →NRXPNRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
RADNOR, Pa., March 18, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage pharmaceutical company, announced today that the company's Board of Directors appointed Ira Strassberg as Chief Financial Officer and Treasurer effective March 15, 2022. "Ira h
Read more →NRXPNRx Pharmaceuticals Announces Leadership Transition Robert Besthof, Head of Operations and Chief Commercial Officer, Appointed Interim CEO Jonathan Javitt, MD, MPH, to Serve as a Consultant and Chief Scientist and Remain
NRx Pharmaceuticals Announces Leadership Transition Robert Besthof, Head of Operations and Chief Commercial Officer, Appointed Interim CEO Jonathan Javitt, MD, MPH, to Serve as a Consultant and Chief Scientist and Remain on the Board of Directors RADNOR, Pa., March 8, 2022 -
Read more →NRXP(NRXP; NRXPW) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading NRx Pharmaceuticals Class Action Lawsuit
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW). The class action is on behalf of shareholders who purchased
Read more →NRXPNRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine
Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaper BriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines, according to IIBR findings RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx
Read more →NRXPNRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules RADNOR , Pa.
NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules RADNOR, Pa., February 2, 2022 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has c
Read more →NRXPNRX PHARMACEUTICALS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against NRx Pharmaceuticals, Inc. in the United States District Court for the District of Delaware
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP; NRXPW) filed in the United States District Court
Read more →NRXPNRXP; NRXPW Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: March 21, 2022
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP; NRXPW) on behalf of purchasers of NRx secur
Read more →NRXPNRXP ALERT: Robbins Geller Rudman & Dowd LLP Announces that NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, Jan. 23, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”)
Read more →NRXPNRx Pharmaceuticals Announces Expansion of ZYESAMI (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments
ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH) NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Administration guidelines NRx is also mak
Read more →NRXPNRx Responds to Relief’s Allegations of January 14, 2022
Neither NRx nor Jonathan Javitt accused current Relief management or board of a criminal past. The lawsuit identifies FINRA actions against Dr. Sevelraju, prior securities investigation, and civil fines against Dr. John Paul Waymack, and a prior securities fraud conviction, incar
Read more →NRXPNRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant
Trial targeted to begin in the first quarter of 2022 NRx is coordinating study with the US Health and Human Services Biomedical Advanced Research and Development Authority and several European Governments Israel Ministry of Health has approved first-in-human trial of intraderma
Read more →NRXPNRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine
New details of clinical trial for BriLife™ to be discussed during company update presentation at the H.C. Wainwright BioConnect Virtual Conference Company presentation time changed to 9 AM EST on Monday, January 10, 2022 RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharma
Read more →NRXPNRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual Conference
Conference Begins on January 10, 2022 RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be pre
Read more →NRXPNRx Pharmaceuticals Added to the Nasdaq Biotech Index
The Nasdaq Biotechnology Index (NBI) is a market index comprised of Nasdaq® listed Biotechnology and Pharmaceutical companies New classification is effective prior to the market open on Monday, December 20, 2021 RADNOR, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals
Read more →NRXPNRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to Target 640 Patients First Patient in Brazil Expected to be Included in US Natio
Read more →NRXPNRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI and BriLife COVID-19 Vaccine Trials
NRx and Hungary Agree on Regulatory Path for Emergency Use of ZYESAMI Hungary to Serve as First European Nation for the Registrational Phase 2b/3 BriLife COVID Vaccine Trial BUDAPEST, Hungary, Dec. 09, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP) today announced
Read more →NRXPNRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions
Independent Data Safety Monitoring Board has completed review of BriLife phase 2 trial at low, medium, and high doses, with a formal report expected imminently NRx has obtained advice from European Medicines Authority and World Health Organization on phase 2b/3 registration tria
Read more →NRXPNRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI (aviptadil) Treated Patients Previously Administered Remdesivir
Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population Analysis was conducted in response to US Food and Drug Administration
Read more →NRXPNRx Pharmaceuticals Notes New Data on BriLife COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research
Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus Data Suggest that the BriLife Vaccine May Be Capable of Evolvi
Read more →NRXPNRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results
RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning,
Read more →NRXPNRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference
RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Company’s business at the H.C.
Read more →NRXPNRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI (aviptadil) Manufacturing Information
US Food and Drug Administration Review Allows for High Volume Production of ZYESAMI® (aviptadil) Shelf Life of ZYESAMI Now Extended from 62 Days to 150 Days RADNOR, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), today announced receipt of the US Food
Read more →NRXPNRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021
RADNOR, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical-stage, global biopharmaceutical company, today announced that management will report third-quarter 2021 financial results before the market opens on Tuesday, November 16, 2021. The
Read more →NRXPDear Shareholders of NRx Pharmaceuticals, Inc. I am writing to you about the recent lawsuit Relief Therapeutics Holding AG and Relief Therapeutics International SA (together, "Relief") filed against NeuroRx, Inc. ("NRx")
Dear Shareholders of NRx Pharmaceuticals, Inc. I am writing to you about the recent lawsuit Relief Therapeutics Holding AG and Relief Therapeutics International SA (together, "Relief") filed against NeuroRx, Inc. ("NRx"), in New York State Court, claiming that NRx failed to ho
Read more →NRXPBUSINESS Company Overview NRx is a clinical-stage pharmaceutical company which develops, through its wholly-owned operating subsidiaries, NeuroRx, Inc., a Delaware corporation and NeuroRx 2015 LTD, an Israeli corporation
NRx is a clinical-stage pharmaceutical company which develops, through its wholly-owned operating subsidiaries, NeuroRx, Inc., a Delaware corporation and NeuroRx 2015 LTD, an Israeli corporation, novel therapeutics for the treatment of central nervous system disorders and life-
Read more →NRXPNRx Pharmaceuticals Announces Closing of $30 Million Private Placement RADNOR, Pa.
NRx Pharmaceuticals Announces Closing of $30 Million RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Compan
Read more →NRXPNRx Pharmaceuticals Announces $30 Million Private Placement RADNOR, Pa.
NRx Pharmaceuticals Announces $30 Million Private RADNOR, Pa., August 19, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,27
Read more →NRXPNRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021
NRx Pharmaceuticals will report its second quarter 2021 financial results on August 16, 2021, followed by a conference call on August 17, 2021. The call will provide insights into the company's financial performance and updates on its clinical programs. NRx is actively involved in developing treatments for COVID-19 and bipolar depression.
Read more →NRXPNRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA) Newly formed publicly traded company NRx Pharmaceuticals, Inc. (N
NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA) Pa., May 25, 2021 /PRNewswire/ Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq
Read more →NRXPBig Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of
Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with Big Rock Partners Recommends All Stockholders Vote FOR ALL Proposals at Annual NEW YORK, May 21, 2021 Big Rock
Read more →NRXPNeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia RADNOR, Pa. and
NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Pa. and TBLISI, Georgia, April 28, 2021 /PRNewswire/ -- NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze,
Read more →NRXPNeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI Development RADNOR, Pa.
NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding RADNOR, Pa. April 19, 2021 / PRNewswire/ issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx's ability or commitment to deliver a safe, effective, and stable lif
Read more →NRXPNEURORX, INC. AND BIG ROCK PARTNERS ACQUISITION CORP. ANNOUNCE COMMITTED $10 MILLION PIPE TO SUPPORT PROPOSED BUSINESS COMBINATION Wilmington, DE and Delray Beach, FL –
NEURORX, INC. AND BIG ROCK PARTNERS ACQUISITION CORP. COMMITTED $10 MILLION PIPE TO SUPPORT PROPOSED BUSINESS Wilmington, DE and Delray Beach, FL March 15, 2021 NeuroRx, Inc. ( NeuroRx ), a clinical stage-small molecule pharmaceutical company and Big Rock Partners Acquisitio
Read more →NRXPNeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration Feasibility work underway to determine the compatibility of NeuroRx's ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulatio
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Feasibility work underway to determine the compatibility of NeuroRx's ZYESAMI (aviptadil, synthetic VIP) as a dry powder formulation using TFF's Thin-Film Freezing Dry powder inhalation technology has the pot
Read more →NRXPNeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28 Day
NeuroRx Announces that ZYESAMI (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28 Day Interim Endpoint NeuroRx to File for Emergency Use Authorizatio
Read more →NRXPNeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 If Authorized f
reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI (aviptadil) in Hospital Stay among Patients with Respiratory Failure due to If Authorized for Use, ZYESAMI Would be First Treatment Specifically for Critically Ill Patients with Respiratory
Read more →NRXPNeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial RADNOR, Pa. and GENEVA
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI (RLF-100 : aviptadil) in the I-SPY COVID-19 RADNOR, Pa. and GENEVA, Jan. 11, 2021 /PRNewswire/ NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ( Relief ), and the Quantum Leap Healt
Read more →NRXPBIG ROCK PARTNERS ACQUISITION CORP. ANNOUNCES MERGER WITH NEURORX, INC. COMBINED COMPANY TO HAVE AN ESTIMATED POST-TRANSACTION EQUITY VALUE IN EXCESS OF $500 MILLION (EXCLUDING POTENTIAL EARNOUT PAY
BIG ROCK PARTNERS ACQUISITION CORP. ANNOUNCES MERGER WITH NEURORX, COMBINED COMPANY TO HAVE AN ESTIMATED POST-TRANSACTION EQUITY VALUE IN EXCESS OF $500 MILLION (EXCLUDING POTENTIAL EARNOUT PAYMENTS), ASSUMING A SHARE PRICE OF AT LEAST $10.00 PER SHARE NeuroRx, Inc. is a clin
Read more →NRXPBig Rock Partners Acquisition Corp. Announces Extension of Time to Consummate Business Combination NEW YORK, NY / ACCESSWIRE /
Big Rock Partners Acquisition Corp. Announces Extension of Time to Consummate Business Combination NEW YORK, NY / ACCESSWIRE / February 22, 2019 / Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) (the "Company" or "Big Rock Partners") today announced that its sponsor, Big R
Read more →NRXPBig Rock Partners Acquisition Corp. Announces Intent to Extend Deadline to Complete Business Combination NEW YORK, NY / ACCESSWIRE /
Big Rock Partners Acquisition Corp. Announces Intent to Extend to Complete Business Combination NEW YORK, NY / ACCESSWIRE / November 19, 2018 / Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) (the "Company" or "Big Rock Partners") today announced that its sponsor, Big Rock
Read more →NRXPBIG ROCK PARTNERS ACQUISITION CORP. INDEX TO FINANCIAL STATEMENTS F. Page Report of Independent Registered Pubic Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statements F-4 F-1 REPORT OF INDEPENDENT REGISTERE
BIG ROCK PARTNERS ACQUISITION CORP. INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Pubic Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statements F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING Audit Committee of the Board of Direct
Read more →NRXPBig Rock Partners Acquisition Corp. Announces Pricing of $60 Million Initial Public Offering NEW YORK, NY / ACCESSWIRE /
Big Rock Partners Acquisition Corp. Announces Pricing of $60 Million Initial Public Offering NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Big Rock Partners Acquisition Corp. (NASDAQ: BRPAU) (the "Company" or "Big Rock Partners") today announced the pricing of its initial p
Read more →Competitive Position
How NRXP ranks across every disease it competes inCompetitive Position is a premium feature
See how NRXP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial